Revance is more than a biotechnology company with a novel drug-delivery platform. We are the integrated sum of our many strengths.
Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of products that achieve multiple strategic objectives.
We like to dream and think big. Our organization owns aspirations of becoming a global leader in both aesthetic medicine and underserved therapeutic specialties such as as dermatology, neurology, urology, and ophthalmology.
Currently, Revance is advancing two investigational product candidates. Each has the potential to expand practitioner and patient utilization, with the opportunity to capture, retain and grow significant market share.
While our first indications will be used in aesthetic medicine to treat facial wrinkles, we plan to follow with improved therapeutic options that deliver enhanced results, irrespective of use area. Our ultimate mission is to improve the overall patient experience. We know it can be done and we aim to prove it.
Closing share price
|FY, 2015||FY, 2014|
|$300 K||$383 K|
|$-73.5 M||$-62.9 M|